Molecular detection of TEM broad spectrum β-lactamase in clinical isolates of Escherichia coli

African Journal of Biotechnology

Volumn 10, Issue 46, 2011, Pages 9454-9458

  Sharifi Yazdi, Mohammad Kazem ^a   Soltan Dallal, Mohammad Mehdi ^a   Agha Mirzaei, Hedroosha Molla ^a   Sabbaghi, Ailar ^a   Mehrabadi, Jalil Fallah ^b   Lari, Abdolaziz Rastegar ^a   Eshraghian, Mohammad Reza ^a   Saneiee, Atefeh Fard ^a   Abdar, Mojtaba Hanafi ^c   Bakhtiari, Ronak ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Bioinformatics Institute   (Iran)

^c SHAHED UNIVERSITY   (Iran)

Author keywords

Escherichia coli; lactamase enzymes; TEM type extended spectrum beta lactamases

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTAZIDIME; CEPATOZIDIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; NALIDIXIC ACID; OXYIMINOCEPHALOSPORIN; STREPTOMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BLA TEM GENE; CONTROLLED STUDY; DISK DIFFUSION; DRUG EFFICACY; ESCHERICHIA COLI; GENE EXPRESSION; GENE IDENTIFICATION; IRAN; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY;

ESCHERICHIA COLI;

EID: 80052144002     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: 10.5897/ajb10.834     Document Type: Article

References (24)

1. Bradford PA (2001). Extended-spectrum beta¬-lactamases in the 21st century: characterization, epidemiology and detection of this important resistance threat. Clin. Microbiol. Rev. 14(4): 933-951.
2. Chaïbi EB, Sirot D, Paul G, Labia R (1999). Inhibitor-resistant TEM ßlactamases: phenotypic, genetic and biochemical characteristics. J. Antimicrob. Chemother 43(4): 447-458.
3. Chouchani C, Ben-Achour N, M'charek A, Belhadj O (2007). Cefotaxime and ceftazidime-resistant Escherichia coli isolate producing TEM-15 β-lactamase from a Tunisian hospital. C. R. Biol 330(8): 565-570.
4. Clinical and Laboratory Standards Institute (CLSI)(2005). Performance standards for antimicrobial susceptibility testing: Fifteenth Informational Supplement. M100-S15. 14th Ed. CLSI, Wayne, PA, USA.
5. Coque TM, Baquero F, Canton R (2008). Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Eurosurveillance 13(47): 1-40.
6. Coudron PE, Moland ES, Thomson KS (2000). Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center. J. Clin. Microbiol. 38(5):1791-1796.
7. Deshpande LM, Jones RN, Fritsche TR, Sader HS (2006). Occurrence of plasmidic AmpC type β-lactamase-mediated resistance in Escherichia coli: report from the Sentry Antimicrobial Surveillance Program (North Am. 2004). Int. J. Antimicrob. Agents 28(6): 578-581.
8. Fang H, Ataker F, Hedin G, Dornbusch K (2008). Molecular epidemiology of extended-spectrum β-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J. Clin. Microbiol. 46(2): 707-712.
9. Goossens H, Grabein B (2005). Prevalence and antimicrobial susceptibility data for extended-spectrum β-lactamase and AmpCproducing Enterobacteriaceae from the MYSTIC program in Europe and the United States (1997-2004). Diagn. Microbiol. Infect. Dis. 53(4): 257-264.
10. Gupta V (2007). An update on newer beta-lactamases. Indian. J. Med. Res. 126(5): 417-427.
11. Harada S, Ishii Y, Yamaguchi K (2008). Extended-spectrum β-lactamases: implications for the clinical laboratory and therapy. Korean. J. Lab. Med. 28(6): 401-412.
12. Hosoglu S, Gundes S, Kolayli F, Karadenizli A, Demirdag K, Gunaydin M, Altindis M, Caylan R, Ucmak H (2007). Extended-spectrum betalactamases in ceftazidime resistant Escherichia coli and Klebsiella pneumoniae isolates in Turkish hospitals. Indian. J. Med. Microbiol. 25(4):346-350.
13. Mammeri H, Gilly L, Laurans G, Vedel G, Eb F, Paul G (2001). Catalytic and structural properties of IRT-21 beta-lactamase (TEM-77) from a co-amoxiclav-resistant Proteus mirabilis isolate. FEMS. Microbiol. Lett, 205(2): 185-189.
14. Netzel TC, Jindani I, Hanson N, Turner BM, Smith L, Rand KH (2007). The AmpC inhibitor, Syn2190, can be used to reveal extendedspectrum β-lactamases in Escherichia coli. Diagn. Microbiol. Infect. Dis 58(3): 345-348.
15. Paterson DL, Bonomo RA (2005). Extended-spectrum β lactamases: a clinical update. Clin. Microbiol. Rev. 18(4): 657-686.
16. Pérez-Pérez FJ, Hanson ND (2002). Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol. 40(6):2153-2162.
17. Rupp ME, Fey PD (2003). Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs. 63(4):353-365.
18. Soltan Dallal MM, Molla Aghamirzaei H, Fallah Mehrabadi J, Rastegar Lari A, Sabbaghi A, Eshraghian MR (2010). Molecular detection of TEM and AmpC (Dha, mox) broad spectrum β-lactamase in clinical isolates of Escherichia coli. Tehran Univ. Med. J. 68(6): 315-320.
19. Song W, Bae K, Lee YN, Lee CH, Lee SH, Jeon SH (2007). Detection of extended-spectrum β-lactamases by using Boronic acid as an AmpC β-lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli. J. Clin. Microbiol. 45(4): 1180-1184.
20. Tasli H, Bahar IH (2005). Molecular characterization of TEM and SHV derived extended spectrum beta-lactamases in hospital-based Entrobacteriaceae in Thurkey. Jpn. J. Infect. Dis. 58(3):162-167.
21. Tenover F¬C, Raney PM, Williams PP, Rasheed K, Biddle JW, Oliver A, Fridkin SK, Jevitt L, McGowan JE (2003). Evaluation of the NCCLS extended-spectrum β-lactamase confirmation methods for Escherichia coli with isolates collected during project ICARE. J. Clin. Microbiol. 41(7): 3142-3146.
22. Vakulenko S, Golemi D (2002). Mutant TEM β-lactamase producing resistance to ceftazidime, ampicillins and β¬-lactamase inhibitors. Antimicrob. Agents. Chemother. 46(3):646-653.
23. Valvered EDR, Padilla TP, Hernandez AH, Grande RP, Vázquez MF, García IG, García-Rodríguez JA, Muñoz Bellido, JL (2007). Prevalence of clinical isolates of Escherichia coli and Klebsiella spp. producing multiple extended-spectrum beta-lactamase. Diagn. Microbiol. Infect. Dis. 59(4): 433-437.
24. Zhang Z, Guo X, Zhang Q (2009). Prevalence characterization of extended-spectrum β-lactamases among Escherichia coli isolates collected in Zhengzhou. J. Clin. Lab. Anal. 23(6):404-407.